The final results have been complex by uneven distribution of ApoE4 carriers concerning placebo and treatment method groups, which was a result of an EMA ask for over the trial. A subgroup copyrightination, introduced at CTAD, recommended that the therapy gain was not as a consequence of this imbalance (